Back to homepage

Haematology and Oncology

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

Authors: Shinichi Makita MD, PhD, Katsuaki Imaizumi Ph, Saiko Kurosawa MD, Kensei Tobinai MD, PhD

In this review, the recent clinical developments, clinical implications, and perspectives of CAR T-cell therapy are summarized, focusing on B-cell NHL

More

Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

Authors: Melissa E Badowski PharmD, MPH, Bradley Burton PharmD, Kristy M Shaeer PharmD, MPH, John Dicristofano BS, PharmD Candidate

This article evaluates existing literature through such means as drug databases and package inserts along with PubMed/Medline, Embase, and Google Scholar databases to develop a reference tool for providers to utilize when there is a decision to treat a patient with ART and oral oncolytic agents concurrently.

More

Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations

Authors: Marisa C Liu MD, MPH, Krishnansu S Tewari MD

This review summarizes studies related to anti-angiogenic treatment, synthetic lethality, and checkpoint inhibition of ovarian cancer and additionally novel combinations that offer a veritable therapeutic matrix for clinicians to choose from.

More

A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Authors: Mariane Teodoro Fernandes MD, Jacob J Adashek BA, Carmelia Maria Noia Barreto MD, Ana Cláudia Barbin Spinosa MD, Barbara de Souza Gutierres MSc, Gilberto Lopes MD, MBA, FAMS, Auro del Giglio MD, PhD, Pedro Nazareth Aguiar Jr MD, MSc

A novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In this review, all available data is summarized, unanswered questions are highlighted, and pharmacological differences between each CDK4/6 inhibitor are discussed.

More

The biosimilars journey: current status and ongoing challenges

Authors: Igor Age Kos MD, Valderílio Feijó Azevedo MD, PhD, Daniel Egg Neto, Sérgio Cândido Kowalski MD, PhD

Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.

More